

**UNITED STATES DISTRICT COURT
SOUTHERN DISTRICT OF NEW YORK**

IN RE STEMLINE THERAPEUTICS, INC.
SECURITIES LITIGATION

Master File No. 1:17-CV-00832-PAC

CLASS ACTION

NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF CLASS ACTION

If you purchased or otherwise acquired Stemline Therapeutics, Inc. (“Stemline” or the “Company”) common stock during the period from January 20, 2017 to February 1, 2017, both dates inclusive (the “Settlement Class Period”), and/or pursuant or traceable to Stemline’s secondary public offering on or about January 20, 2017 (the “SPO”), you could get a payment from a proposed class action settlement (the “Settlement”).

Under law, a federal court has authorized this Notice. This is not attorney advertising.

- If approved by the Court, the Settlement will provide six hundred eighty thousand dollars (\$680,000) (the “Settlement Amount”) gross, plus interest as it accrues, minus attorneys’ fees, costs, administrative expenses, and net of any taxes on interest, to pay claims of investors who purchased or otherwise acquired Stemline common shares during the Settlement Class Period and/or pursuant or traceable to Stemline’s SPO.
- The Settlement represents an estimated average recovery of \$0.11 per allegedly damaged share of Stemline’s common stock purchased or otherwise acquired during the Settlement Class Period and/or pursuant or traceable to Stemline’s SPO. This is based on Plaintiffs’ expert’s estimate of approximately 6.2 million allegedly damaged shares. This is not an estimate of the actual recovery per share you should expect. Your actual recovery will depend on the aggregate losses of all Settlement Class Members, the date(s) you purchased (or otherwise acquired) and sold Stemline common stock, and the total number of claims filed.
- Attorneys for Lead Plaintiffs (“Plaintiffs’ Counsel”) will ask the Court to award them fees of up to \$226,667 (one-third of the Settlement Amount) plus interest, reimbursement of no more than \$50,000 in litigation expenses, and an Award to Lead Plaintiffs and Representative Plaintiff collectively not to exceed \$4,000 (\$1,000 each). If approved by the Court, these amounts (totaling an average of \$0.045 per Stemline allegedly damaged share) will be paid from the Settlement Fund.
- The average approximate recovery, after deduction of attorneys’ fees and interest and expenses approved by the Court, is \$0.065 per Stemline allegedly damaged share. This estimate is based on the assumptions set forth in the preceding paragraphs. Your actual recovery, if any, will depend on the aggregate losses of all Settlement Class Members, the date(s) you purchased (or otherwise acquired) and sold Stemline common stock, the purchase and sale prices, and the total number and amount of claims filed.
- The Settlement resolves the Action against Stemline, certain of its officers and directors, and an underwriter of the SPO (collectively “Defendants”), which alleged violations of federal securities laws premised upon the allegation that Defendants allegedly made misrepresentations and/or omissions of material fact, including in connection with the SPO, related to the clinical trial for one of Stemline’s drug candidates. The Court dismissed the Action on March 15, 2018, and entered judgment in favor of Defendants on April 13, 2018. Plaintiffs then filed an appeal with the U.S. Court of Appeals for the Second Circuit. Defendants have denied and continue to deny each, any and all allegations of wrongdoing, fault, liability or damage whatsoever asserted by Plaintiffs. Defendants have also denied, *inter alia*, the allegations that Plaintiffs or the Settlement Class have suffered damages or that Plaintiffs or the Settlement Class were harmed by the conduct alleged in the Action. Defendants continue to believe the claims asserted against them in the Action are without merit. While the case was on appeal, Plaintiffs and Defendants agreed to settle the case.
- Your legal rights will be affected whether you act or do not act. If you do not act, you may permanently forfeit your right to recover on this claim. Therefore, you should read this Notice carefully.

YOUR LEGAL RIGHTS AND OPTIONS IN THIS SETTLEMENT	
Submit a Claim Form	Fill out the attached Proof of Claim and Release form and submit it no later than October 23, 2019 . This is the only way to get a payment.
Exclude Yourself from the Class	Submit a request for exclusion no later than September 2, 2019 . This is the only way you can ever be part of any other lawsuit against the Defendants or the other Released Parties about the legal claims in this case. If you exclude yourself, you will receive no payment and cannot object or speak at the hearing.
Object	Write to the Court no later than September 2, 2019 about why you do not like the Settlement. You can still submit a claim form. If the Court approves the Settlement, you will be bound by it.
Go To The Hearing	Ask to speak in Court about the fairness of the Settlement at the hearing on September 23, 2019 . You can still submit a claim form. If the Court approves the Settlement, you will be bound by it.
Do Nothing	Get no payment AND give up your right to bring your own individual action.

INQUIRIES

Please do not contact the Court regarding this Notice. All inquiries concerning this Notice, the Proof of Claim and Release Form, or the Settlement should be directed to:

Stemline Therapeutics, Inc. Securities Litigation c/o Strategic Claims Services P.O. Box 230 600 N. Jackson St., Ste. 205 Media, PA 19063 Tel.: 866-274-4004 Fax: 610-565-7985 info@strategicclaims.net	or	Jacob A. Goldberg, Esq. Laurence M. Rosen, Esq. THE ROSEN LAW FIRM, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel.: 212-686-1060 Fax: 212-202-3827
--	-----------	---

DEFINITIONS

All capitalized terms not otherwise defined herein shall have the same meanings as set forth in the Stipulation and Agreement of Settlement, dated March 11, 2019 (the “Settlement Stipulation”).

COMMON QUESTIONS AND ANSWERS CONCERNING THE SETTLEMENT

1. Why did I get this Notice?

You or someone in your family may have purchased or otherwise acquired publicly-traded common stock of Stemline from January 20, 2017 to February 1, 2017, both dates inclusive, and/or pursuant or traceable to Stemline’s secondary public offering of common stock on or about January 20, 2017.

2. What is this lawsuit about?

The case is known as *In re Stemline Therapeutics, Inc. Securities Litigation*, Master File No. 1:17-CV-00832-PAC (S.D.N.Y.) (the “Action”), and alleged violations of the federal securities laws premised upon the allegation that Defendants allegedly made misrepresentations and/or omissions of material fact, including in connection with the SPO, related to the clinical trial for one of Stemline’s drug candidates. The Court in charge of the case is the United States District Court for the Southern District of New York (the “Court”). This matter has not gone to trial. The Court dismissed the Action on March 15, 2018, and entered judgment in favor of Defendants on April 13, 2018. Plaintiffs then filed an appeal with the U.S. Court of Appeals for the Second Circuit. While the case was on appeal, Plaintiffs and Defendants agreed to settle the case.

Defendants have denied and continue to deny each, any and all allegations of wrongdoing, fault, liability or damage whatsoever asserted in the Action, which was dismissed by the Court for failure to state a claim upon which relief could be granted, which dismissal was appealed by Plaintiffs to the U.S. Court of Appeals for the Second Circuit. The Settlement shall in no event be construed as, or deemed to be evidence of, liability, fault, wrongdoing, injury or damages, or of any wrongful conduct, acts or omissions on the part of any of the Defendants or their “Related Parties” (as defined in the Settlement Stipulation), or of any infirmity of any defense, or of any damages to the Plaintiffs or any other Settlement Class Member. The Settlement resolves all of the claims in the Action, as well as certain other claims or potential claims, whether known or unknown.

3. Why is this a class action?

In a class action, one or more persons and/or entities, called plaintiffs, sue on behalf of all persons and/or entities who have similar claims. All of these persons and/or entities are referred to collectively as a class, and these individual persons and/or entities are known as class members. One court resolves all of the issues for all class members, except for those class members who exclude themselves from the class.

4. Why is there a Settlement?

Plaintiffs and Defendants do not agree regarding the merits of Plaintiffs’ allegations and Defendants’ defenses with respect to liability or the average amount of damages per share, if any, that would be recoverable if Plaintiffs were to prevail at trial on each claim. The issues on which Plaintiffs and the Defendants disagree include, among others: (1) whether the challenged statements were materially false or misleading or otherwise actionable under federal securities law; (2) whether the Defendants acted with scienter; (3) whether the alleged disclosures were corrective disclosures; (4) the causes of the loss in the value of the securities; and (5) the amount of alleged damages, if any, that could be recovered at trial.

This matter has not gone to trial. The Court dismissed the action on March 15, 2018, and entered judgment in favor of Defendants on April 13, 2018. Plaintiffs then filed an appeal with the U.S. Court of Appeals for the Second Circuit. While the case was on appeal, Plaintiffs and Defendants agreed to settle the case. Plaintiffs and Plaintiffs’ Counsel believe the Settlement is best for all Settlement Class Members because of the risks associated with continued litigation and the nature of the defenses raised by the Defendants. Among the reasons that Plaintiffs and Plaintiffs’ Counsel believe the Settlement is fair is the fact that there is uncertainty about whether they will be able to prevail on appeal, and, if they do so prevail, to prove that any challenged statement was false or misleading, that the alleged misstatements and omissions actually caused the Settlement Class any damages, and the amount of damages, if any.

Even if Plaintiffs were to succeed in reversing the district court’s decision to dismiss the case, then win at trial, and also prevail on any on appeal, Plaintiffs might not be able to collect some, or all, of any judgment they are awarded. Moreover, while litigation of this type is usually expensive, it appears that, even if Plaintiffs’ allegations were found to be true, the total amount of damages to which Settlement Class Members would be entitled could be substantially reduced.

5. How do I know if I am part of the Settlement?

The Settlement Class consists of those persons who purchased or otherwise acquired Stemline common stock (i) during the Settlement Class Period of January 20, 2017, through February 1, 2017, both dates inclusive, and/or (ii) pursuant or traceable to Stemline’s SPO and were allegedly damaged thereby. Excluded from the Settlement Class are Defendants, current and former officers and directors of Stemline or Jefferies LLC (“Jefferies”), members of the Defendants’ immediate families, as well as the Defendants’ legal representatives, heirs, successors or assigns, and any entity in which Defendants have or had a majority ownership interest. Also excluded from the Settlement Class are those Persons who file valid and timely requests for exclusion in accordance with the Preliminary Approval Order entered by the Court.

6. Are there exceptions to being included?

Yes. Excluded from the Settlement Class are Defendants, current and former officers and directors of Stemline or Jefferies, members of the Defendants’ immediate families, as well as the Defendants’ legal representatives, heirs, successors or assigns, and any entity in which Defendants have or had a majority ownership interest. You are also excluded from the Class if you have a net profit in purchases and

sales of Stemline securities or otherwise suffered no compensable damages during the Settlement Class Period. Also excluded from the Settlement Class are those Persons who file valid and timely requests for exclusion in accordance with the Preliminary Approval Order entered by the Court as described below in the response to question 11.

7. I am still not sure whether I am included.

If you are still not sure whether you are included, you can ask for free help. For more information, you can contact the Claims Administrator, Strategic Claims Services, by phone at (866) 274-4004 or by facsimile at (610) 565-7985, visit the website www.strategicclaims.net, or fill out and return the Proof of Claim and Release Form described in Question 9, to see if you qualify.

8. What does the Settlement provide?

a. What is the Settlement Fund?

The proposed Settlement provides for Stemline or its insurer to pay six hundred eighty thousand dollars (\$680,000) into a settlement fund (the “Settlement Fund”). The Settlement is subject to Court approval. Also, subject to the Court’s approval, a portion of the Settlement Fund will be used to pay attorneys’ fees with interest and reasonable litigation expenses to Plaintiffs’ Counsel, and any Award to Lead Plaintiffs and Representative Plaintiff. A portion of the Settlement Fund also will be used to pay taxes due on interest earned by the Settlement Fund, if necessary, and the costs of the claims administration, including the costs of printing and mailing this Notice and the costs of publishing notice. After the foregoing deductions from the Settlement Fund have been made, the amount remaining (the “Net Settlement Fund”) will be distributed to Settlement Class Members who submit timely, valid claims, according to the Plan of Allocation to be approved by the Court.

b. What can you expect to receive under the proposed Settlement?

Your share of the Net Settlement Fund will or may depend on: (i) the number of claims filed by all Settlement Class Members; (ii) the dates you purchased (or otherwise acquired) and sold Stemline common stock; (iii) the prices of your purchases and sales; (iv) the amount of administrative costs, including the costs of notice; and (v) the amount awarded by the Court to Plaintiffs’ Counsel for attorneys’ fees, costs, and expenses and to the Lead Plaintiffs and Representative Plaintiff.

The Net Settlement Fund will be distributed to Settlement Class Members who submit a Proof of Claim and Release Form and whose claims for recovery are allowed by the Claims Administrator pursuant to the terms of the Settlement Stipulation or by order of the Court under the below Plan of Allocation (“Authorized Claimants”), which reflects Plaintiffs’ contention that because of the alleged misrepresentations made by Defendants, the price of Stemline common stock was artificially inflated during the relevant period, and that certain subsequent disclosures caused changes in the allegedly inflated price of Stemline common stock. Defendants have denied and continue to deny these allegations and any and all allegations of wrongdoing, fault, liability or damage whatsoever asserted in the Action.

PROPOSED PLAN OF ALLOCATION OF THE NET SETTLEMENT FUND

The Plan of Allocation is a matter separate and apart from the proposed Settlement, and any decision by the Court concerning the Plan of Allocation shall not affect the validity or finality of the proposed Settlement. The Court may approve the Plan of Allocation with or without modifications agreed to among the Parties, or another plan of allocation, without further notice to Settlement Class Members. Any orders regarding a modification of the Plan of Allocation will be posted to the Claims Administrator’s website, www.strategicclaims.net.

The Claims Administrator shall determine each Authorized Claimant’s *pro rata* share of the Net Settlement Fund based upon each Authorized Claimant’s Recognized Loss. **Please Note:** The Recognized Loss formula, set forth below, is not intended to be an estimate of the amount of what a Settlement Class Member might have been able to recover after a trial, nor is it an estimate of the amount that will be paid to Authorized Claimants pursuant to the Settlement. The Recognized Loss formula is the basis upon which the Net Settlement Fund will be proportionately allocated to the Authorized Claimants. To the extent there are sufficient funds in the Net Settlement Fund, each Authorized Claimant will receive an amount equal to the Authorized Claimant’s Recognized Loss and subject to the provisions in the preceding paragraph. If, however, the amount in the Net Settlement Fund is not sufficient to permit payment of the total Recognized Loss of each Authorized Claimant, then each Authorized Claimant shall be paid the

percentage of the Net Settlement Fund that each Authorized Claimant's Recognized Loss bears to the total Recognized Losses of all Authorized Claimants and subject to the provisions in the preceding paragraph (i.e., "pro rata share"). Payment in this manner shall be deemed conclusive against all Authorized Claimants. No distribution will be made on a claim where the potential distribution amount is less than ten dollars (\$10.00) in cash.

If any funds remain in the Net Settlement Fund by reason of uncashed checks, or otherwise, after the Claims Administrator has made reasonable and diligent efforts to have Authorized Claimants who are entitled to participate in the distribution of the Net Settlement Fund cash their distribution checks, then any balance remaining in the Net Settlement Fund six (6) months after the initial distribution of such funds shall be used: (i) first, to pay any amounts mistakenly omitted from the initial distribution to Authorized Claimants; (ii) second, to pay any additional Administration Costs incurred in administering the Settlement; and (iii) finally, to make a second distribution to Authorized Claimants who cashed their checks from the initial distribution and who would receive at least \$10.00 from such second distribution, after payment of the estimated costs or fees to be incurred in administering the Net Settlement Fund and in making this second distribution, if such second distribution is economically feasible. If six (6) months after such second distribution, if undertaken, or if such second distribution is not undertaken, any funds shall remain in the Net Settlement Fund after the Claims Administrator has made reasonable and diligent efforts to have Authorized Claimants who are entitled to participate in this Settlement cash their checks, any funds remaining in the Net Settlement Fund shall be donated to a non-profit charitable organization(s) selected by Lead Counsel.

THE BASIS FOR CALCULATING YOUR RECOGNIZED LOSS:

Each Authorized Claimant shall be allocated a *pro rata* share of the Net Settlement Fund based on his, her or its Recognized Loss as compared to the total Recognized Losses of all Authorized Claimants. Recognized Losses will be calculated as follows:

D) For Stemline common shares purchased or otherwise acquired between January 20, 2017 and February 1, 2017, inclusive, **pursuant or traceable to the SPO**, the Recognized Loss shall be calculated as follows:

- A. For shares sold on or before February 1, 2017¹, the Recognized Loss, shall be zero.
- B. For shares sold on February 2, 2017 or February 3, 2017², the Recognized Loss shall be the lesser of:
 - i. \$10.00 per share³ (the SPO price) less the sale price per share; or
 - ii. \$4.15 per share⁴.
- C. For shares held as of the close of trading on February 3, 2017, the Recognized Loss shall be \$3.45 per share⁵.

II) For Stemline common shares purchased or otherwise acquired between January 20, 2017 and February 1, 2017, inclusive, **not pursuant or traceable to the SPO**, the Recognized Loss shall be calculated as follows:

- A. For shares retained at the end of trading on May 2, 2017, the Recognized Loss shall be the lesser of:
 - (i) \$4.15 per share; or
 - (ii) the difference between the purchase price per share and \$8.12 per share⁶.

¹ This the end of the Settlement Class Period.

² This is the date the initial suit was filed.

³ \$10 per share is the SPO price on January 20, 2017.

⁴ \$4.15 is the maximum inflation per share.

⁵ \$3.45 per share is the difference between the \$10 per share SPO price and the \$6.55 per share price of Stemline common shares at the close of trading on February 3, 2017, the date of the initial suit.

⁶ Pursuant to Section 21(D)(e)(1) of the Private Securities Litigation Reform Act of 1995, "in any private action arising under this title in which the plaintiff seeks to establish damages by reference to the market price of a security, the award of damages to the plaintiff shall not exceed the difference between the purchase or sale price paid or received, as appropriate, by the plaintiff for the subject security and the mean trading price of that security during the 90-day period beginning on the date on which the information correcting the misstatement or omission that is the basis for the action is disseminated." \$8.12 per share was the

- B. For shares sold on or before February 1, 2017, the Recognized Loss per share shall be \$0.
- C. For each share sold between February 2, 2017 and May 2, 2017, inclusive, the Recognized Loss shall be the lesser of:
- i) \$4.15 per share: or
 - ii) the difference between the purchase price per share and the average closing price per share as of date of sale provided in table A below.

Table A						
<u>Date</u>	<u>Closing Price</u>	<u>Average Closing Price</u>		<u>Date</u>	<u>Closing Price</u>	<u>Average Closing Price</u>
2/2/2017	\$5.60	\$5.60		3/20/2017	\$9.60	\$7.71
2/3/2017	\$6.55	\$6.08		3/21/2017	\$8.70	\$7.74
2/6/2017	\$6.30	\$6.15		3/22/2017	\$8.95	\$7.77
2/7/2017	\$6.20	\$6.16		3/23/2017	\$8.50	\$7.79
2/8/2017	\$6.65	\$6.26		3/24/2017	\$8.45	\$7.81
2/9/2017	\$6.95	\$6.38		3/27/2017	\$8.55	\$7.83
2/10/2017	\$6.85	\$6.44		3/28/2017	\$8.30	\$7.84
2/13/2017	\$6.95	\$6.51		3/29/2017	\$8.45	\$7.86
2/14/2017	\$6.95	\$6.56		3/30/2017	\$8.35	\$7.87
2/15/2017	\$6.60	\$6.56		3/31/2017	\$8.55	\$7.89
2/16/2017	\$6.40	\$6.55		4/3/2017	\$8.15	\$7.90
2/17/2017	\$6.80	\$6.57		4/4/2017	\$7.85	\$7.89
2/21/2017	\$6.95	\$6.60		4/5/2017	\$7.75	\$7.89
2/22/2017	\$6.65	\$6.60		4/6/2017	\$8.25	\$7.90
2/23/2017	\$6.45	\$6.59		4/7/2017	\$8.30	\$7.91
2/24/2017	\$6.85	\$6.61		4/10/2017	\$8.50	\$7.92
2/27/2017	\$7.05	\$6.63		4/11/2017	\$8.30	\$7.93
2/28/2017	\$7.00	\$6.65		4/12/2017	\$8.15	\$7.93
3/1/2017	\$8.00	\$6.72		4/13/2017	\$8.30	\$7.94
3/2/2017	\$8.25	\$6.80		4/17/2017	\$8.95	\$7.96
3/3/2017	\$8.80	\$6.90		4/18/2017	\$8.55	\$7.97
3/6/2017	\$8.45	\$6.97		4/19/2017	\$8.70	\$7.98
3/7/2017	\$8.00	\$7.01		4/20/2017	\$8.90	\$8.00
3/8/2017	\$8.15	\$7.06		4/21/2017	\$8.65	\$8.01
3/9/2017	\$8.80	\$7.13		4/24/2017	\$8.75	\$8.03
3/10/2017	\$9.75	\$7.23		4/25/2017	\$9.10	\$8.05
3/13/2017	\$9.90	\$7.33		4/26/2017	\$9.45	\$8.07
3/14/2017	\$9.75	\$7.41		4/27/2017	\$9.05	\$8.09
3/15/2017	\$9.80	\$7.50		4/28/2017	\$8.90	\$8.10
3/16/2017	\$10.15	\$7.59		5/1/2017	\$8.65	\$8.11
3/17/2017	\$9.50	\$7.65		5/2/2017	\$8.65	\$8.12

To the extent a Claimant had a trading gain or “broke even” from his, her or its overall transactions in Stemline shares during the Settlement Class Period, the value of the Recognized Loss

mean (average) daily closing trading price of the Company’s common shares during the 90-day period beginning on February 2, 2017 and ending on May 2, 2017.

will be zero, and the Claimant will not be entitled to a share of the Net Settlement Fund. To the extent that a Claimant suffered a trading loss on his, her or its overall transactions in Stemline shares during the Settlement Class Period, but that trading loss was less than the Recognized Loss calculated above, then the Recognized Loss shall be limited to the amount of the Claimant's actual trading loss.

For purposes of calculating your Recognized Loss, the date of purchase, acquisition or sale is the "contract" or "trade" date and not the "settlement" or "payment" date. The receipt or grant by gift, inheritance or operation of law of Stemline shares shall not be deemed a purchase, acquisition or sale of Stemline shares for the calculation of an Authorized Claimant's Recognized Loss. The covering purchase of a short sale is not an eligible purchase. Only publicly traded common shares are eligible purchases.

For purposes of calculating your Recognized Loss, all purchases, acquisitions and sales shall be matched on a First In First Out ("FIFO") basis in chronological order. Therefore, on the Proof of Claim and Release Form enclosed with this Notice, you must provide all of your purchases and acquisitions of Stemline common shares during the time period from January 20, 2017 through and including May 2, 2017.

Payment pursuant to the Plan of Allocation approved by the Court shall be conclusive against all Authorized Claimants. Defendants and their Related Parties shall have no responsibility or liability with respect to the Plan of Allocation, and no person shall have any claim against Defendants or Defendants' Counsel in connection with the Plan of Allocation or any distributions. No person shall have any claim against Plaintiffs, Plaintiffs' Counsel or the Claims Administrator or other agent designated by Plaintiffs' Counsel based on the distributions made substantially in accordance with the Stipulation and the Settlement contained therein, the Plan of Allocation, or further orders of the Court. Each Claimant shall be deemed to have submitted to the jurisdiction of the Court with respect to the Claimant's Claim Form. All persons involved in the review, verification, calculation, tabulation, or any other aspect of the processing of the claims submitted in connection with the Settlement, or otherwise involved in the administration or taxation of the Settlement Fund or the Net Settlement Fund shall be released and discharged from any and all claims arising out of such involvement, and all Settlement Class Members, whether or not they are to receive payment from the Net Settlement Fund, will be barred from making any further claim against the Net Settlement Fund beyond the amount allocated to them as provided in any distribution orders entered by the Court.

9. How can I get a payment?

To qualify for a payment, you must send in a form entitled "Proof of Claim and Release Form." This Proof of Claim and Release Form is attached to this Notice. You may also obtain a Proof of Claim and Release Form at www.strategicclaims.net. Read the instructions carefully, fill out the form, sign it in the location indicated, and mail the claim form together with all documentation requested in the form, **postmarked no later than October 23, 2019**, to:

Stemline Therapeutics, Inc. Securities Litigation
c/o Strategic Claims Services
P.O. Box 230
600 N. Jackson St., Ste. 205
Media, PA 19063
Fax: (610) 565-7985
info@strategicclaims.net

The Claims Administrator will process your claim and determine whether you are an Authorized Claimant.

10. What am I giving up to get a payment or stay in the Class?

Unless you exclude yourself from the Settlement Class by the September 2, 2019 deadline, you will remain a member of the Settlement Class and will be bound by the release of claims against Defendants and their Related Parties (as defined in the Settlement Stipulation) if the Settlement is approved. That means you and all other Settlement Class Members and each of their respective Related Parties, including parent entities, associates, affiliates, subsidiaries, predecessors, successors, and the officers, directors, attorneys, assigns, legal representatives, and agents of each of them, each of their respective officers, directors, attorneys, legal representatives, and agents, and any person or entity which is or was related to or affiliated with any Releasing Party (as defined in the Settlement Stipulation) or in which any Releasing Party has a controlling interest, and each of their respective immediate family members, heirs, representatives, administrators, executors, trustees, successors, assigns, devisees,

legatees, and estates will release (agreeing never to sue, continue to sue, or be part of any other lawsuit) as against Defendants and their Related Parties any and all claims that Plaintiffs or any Settlement Class Member (i) asserted in the Amended Complaint; or (ii) could have asserted in any forum that arise out of or are based upon the allegations, transactions, facts, matters or occurrences, representations or omissions involved, set forth, or referred to in the Amended Complaint and are based on, relate to, or arise out of the purchase, acquisition, holding, or sale or other disposition of Stemline common stock during the Settlement Class Period and/or pursuant or traceable to the SPO. This means that all of the Court's orders will apply to you and legally bind you, and you will accept a share of the Net Settlement Fund as sole compensation for any losses you suffered in the purchase, acquisition, holding, sale, disposition, or ownership of Stemline securities during the Settlement Class Period. The specific terms of the release are included in the Settlement Stipulation.

11. How do I get out of the Settlement?

If you do not want to receive a payment from this Settlement, and you want to keep any right you may have to sue or continue to sue Defendants or their Related Parties on your own about the claims being released in this Settlement, then you must take steps to exclude yourself from the Settlement. To exclude yourself from the Settlement, you must mail a letter that (A) clearly indicates your name, address, phone number and e-mail contact information (if any) and states that you “request to be excluded from the Settlement Class in *In re Stemline Therapeutics, Inc. Securities Litigation*, Master File No. 1:17-CV-00832-PAC (S.D.N.Y.)”, and (B) states the date, number of shares and dollar amount of each Stemline securities purchase or acquisition during the Settlement Class Period and/or pursuant or traceable to the SPO, and any sale transactions as well as the number of shares of Stemline securities held by you as of January 20, 2017, through and including February 1, 2017. In order to be valid, such request for exclusion must be submitted with documentary proof: (i) of each purchase and, if applicable, sale transaction of Stemline securities during the Settlement Class Period; and (ii) demonstrating your status as a beneficial owner of the Stemline securities. Any such request for exclusion must be signed and submitted by you, as the beneficial owner, under penalty of perjury. You must mail your exclusion request, to be **received no later than September 2, 2019**, to the Claims Administrator at the following address:

Stemline Therapeutics, Inc. Securities Litigation
c/o Strategic Claims Services
P.O. Box 230
600 N. Jackson St., Ste. 205
Media, PA 19063

You cannot exclude yourself by telephone or by e-mail.

If you properly exclude yourself, you will not receive a payment from the Net Settlement Fund, you cannot object to the Settlement, and you will not be legally bound by the judgment in this case.

12. If I do not exclude myself, can I sue Defendants or the other Released Parties for the same thing later?

No. Unless you followed the procedure outlined in the Notice to exclude yourself, you give up any right to sue Defendants or their Related Parties for the claims being released in this Settlement. If you have a pending lawsuit related to any Released Claims, speak to your lawyer in that case immediately, since you must exclude yourself from this Settlement Class to continue your own lawsuit.

13. Do I have a lawyer in this case?

The Court appointed The Rosen Law Firm, P.A. and Pomerantz LLP as Lead Counsel, and Glancy Prongay & Murray LLP has served as additional counsel to the Class (collectively “Plaintiffs’ Counsel”), to represent you and the other Settlement Class Members. If you want to be represented by your own lawyer, you may hire one at your own expense. Contact information for The Rosen Law Firm, P.A is provided below.

14. How will the lawyers be paid?

Plaintiffs’ Counsel have expended considerable time litigating this Action on a contingent fee basis and have paid for the expenses of the case themselves. They have not been paid attorneys’ fees or reimbursed for their expenses in advance of this Settlement. Plaintiffs’ Counsel have done so with the expectation that, if they are successful in recovering money for the Settlement Class, they will receive attorneys’ fees and be reimbursed for their litigation expenses from the Settlement Fund, as is

customary in this type of litigation. Plaintiffs' Counsel will not receive attorneys' fees or be reimbursed for their litigation expenses except from the Settlement Fund. Therefore, Plaintiffs' Counsel will file a motion asking the Court at the Settlement Hearing to make an award of attorneys' fees in an amount not to exceed one-third plus interest of the Settlement Amount (\$226,667), reimbursement of litigation expenses of no more than \$50,000 and an Award to Lead Plaintiffs and Representative Plaintiff collectively not to exceed \$4,000 (\$1,000 each). The Court may award less than these amounts. Any amounts awarded by the Court will come out of the Settlement Fund.

15. How do I tell the Court that I do not like the Settlement?

You can tell the Court you do not agree with the Settlement, any part of the Settlement, and/or to Plaintiffs' Counsel's motion for attorneys' fees and expenses and application for an Award to Plaintiffs, and that you think the Court should not approve the Settlement, by mailing a letter stating that you object to the Settlement in the matter of *In re Stemline Therapeutics, Inc. Securities Litigation*, Master File No. 1:17-CV-00832-PAC (S.D.N.Y.). Be sure to include: (1) your name, address, and telephone number; (2) a list of all purchases and sales of Stemline securities during the Settlement Class Period and/or pursuant or traceable to the SPO, in order to show membership in the Settlement Class; (3) all grounds for the objection, including any legal support known to you or your counsel; (4) the name, address and telephone number of all counsel, if any, who represent you, including your former or current counsel who may be entitled to compensation in connection with the objection; and (5) the number of times you and/or your counsel has filed an objection to a class action settlement in the last five years, the nature of each such objection in each case, the jurisdiction in each case, and the name of the issuer of the security or seller of the product or service at issue in each case. Attendance at the Settlement Hearing is not necessary. Objectors wishing to be heard orally at the Settlement Hearing are required to indicate in their written objection (or in a separate writing that is submitted in accordance with the deadline and after instruction pertinent to the submission of a written objection) that they intend to appear at the Settlement Hearing and identify any witnesses they may call to testify or exhibits they intend to introduce into evidence at the Settlement Hearing. Be sure to serve copies of any objections, papers and briefs to **each** of the addresses listed below, to be **received no later than September 2, 2019**:

<p style="text-align: center;">Clerk of the Court United States District Court Southern District of New York 500 Pearl Street New York, NY 10007</p>	<p style="text-align: center;"><i>Plaintiffs' Counsel:</i> Jacob Goldberg, Esq. Laurence M. Rosen, Esq. THE ROSEN LAW FIRM, P.A. 275 Madison Avenue, 34th Floor New York, New York 10016 Telephone: (212) 686-1060 Fax: (212) 202-3827</p>
<p><i>Counsel for Defendants Stemline Therapeutics, Inc., Ivan Bergstein, David Gionco, Ron Bentsur, Eric L. Dobmeier, Alan Forman, and Kenneth Zuerblis:</i> ROPES & GRAY LLP Gregg L. Weiner 1211 Avenue of the Americas New York, New York 10036</p>	<p style="text-align: center;"><i>Counsel for Defendant Jefferies LLC:</i> SHEARMAN & STERLING LLP Adam S. Hakki 599 Lexington Avenue New York, New York 10022-6069</p>

16. What is the difference between objecting and requesting exclusion?

Objecting is simply telling the Court you do not like something about the Settlement or some portion thereof. You can object only if you stay in the Settlement Class. Requesting exclusion is telling the Court you do not want to be part of the Settlement Class and Settlement. If you exclude yourself, you cannot object to the Settlement because it no longer concerns you. If you stay in the Settlement Class and object, but your objection is overruled, you will not be allowed a second opportunity to exclude yourself.

17. When and where will the Court decide whether to approve the Settlement?

The Court will hold a Settlement Hearing on **September 23, 2019, at 11:00 a.m.**, at the United States District Court, Southern District of New York, Daniel Patrick Moynihan United States Courthouse, 500 Pearl Street, Courtroom 14C, New York, New York 10007.

At this hearing, the Court will consider whether the Settlement is fair, reasonable, and adequate and whether to approve the Settlement. If there are objections, the Court will consider them, and the Court will listen to people who have asked to speak at the hearing. The Court may also decide how much to pay Plaintiffs' Counsel for attorneys' fees and expenses and how much to award Lead Plaintiffs.

18. Do I have to come to the hearing?

No. Plaintiffs' Counsel will answer any questions the Court may have. However, you are welcome to attend at your own expense. If you send an objection, you do not have to come to Court to talk about it. As long as you mail your written objection on time, the Court will consider it.

19. What happens if I do nothing at all?

If you do nothing, you will not receive a payment from the Settlement. However, unless you exclude yourself, you will not be able to start a lawsuit, continue with a lawsuit, or be part of any other lawsuit against Defendants or their Related Parties about the Released Plaintiffs' Claims (as defined in the Settlement Stipulation) ever again.

SPECIAL NOTICE TO SECURITIES BROKERS AND OTHER NOMINEES

If, between January 20, 2017 and February 1, 2017, inclusive, you purchased, otherwise acquired, or sold Stemline common stock for the beneficial interest of a person or organization other than yourself, and/or pursuant or traceable to Stemline's secondary public offering of common stock on or about January 20, 2017, and/or you held Stemline common stock as a nominee for the beneficial interest of a person or organization other than yourself that was purchased or acquired between January 20, 2017 and February 1, 2017, and/or pursuant or traceable to Stemline's secondary public offering of common stock on or about January 20, 2017, the Court has directed that, **WITHIN TEN (10) DAYS OF YOUR RECEIPT OF THIS NOTICE**, you either (a) provide to the Claims Administrator the name, last known address and email address of each person or organization for whom or which you purchased or otherwise acquired such Stemline common stock during such time period or (b) request additional copies of this Notice and the Proof of Claim and Release Form, which will be provided to you free of charge, and within ten (10) days mail the Notice and Proof of Claim and Release Form directly to the beneficial owners of the Stemline common stock. If you choose to follow alternative procedure (b), the Court has directed that, upon such mailing, you send a statement to the Claims Administrator confirming that the mailing was made as directed. You are entitled to reimbursement from the Settlement Fund of your reasonable out-of-pocket expenses actually incurred in connection with the foregoing, up to a maximum of \$0.70 per notice. Those expenses will be paid upon request and submission of appropriate supporting documentation. All communications regarding the foregoing should be addressed to the Claims Administrator at the address listed on page 2 above.

DATED: JUNE 14, 2019

**BY ORDER OF THE UNITED STATES
DISTRICT COURT FOR THE SOUTHERN
DISTRICT OF NEW YORK**

PROOF OF CLAIM AND RELEASE FORM

Deadline for Submission: October 23, 2019

IF YOU PURCHASED OR OTHERWISE ACQUIRED STEMLINE THERAPEUTICS, INC. (“STEMLINE” OR THE “COMPANY”) COMMON STOCK DURING THE PERIOD FROM JANUARY 20, 2017 THROUGH FEBRUARY 1, 2017, BOTH DATES INCLUSIVE (THE “SETTLEMENT CLASS PERIOD”), AND/OR PURSUANT OR TRACEABLE TO STEMLINE’S SECONDARY PUBLIC OFFERING OF COMMON STOCK CARRIED OUT ON OR ABOUT JANUARY 20, 2017 (THE “SPO”), AND WERE ALLEGEDLY DAMAGED THEREBY, YOU ARE A “SETTLEMENT CLASS MEMBER” AND YOU MAY BE ENTITLED TO SHARE IN THE SETTLEMENT PROCEEDS. (EXCLUDED FROM THE SETTLEMENT CLASS ARE DEFENDANTS, CURRENT AND FORMER OFFICERS AND DIRECTORS OF STEMLINE OR JEFFERIES LLC, MEMBERS OF THE DEFENDANTS’ IMMEDIATE FAMILIES, AS WELL AS THE DEFENDANTS’ LEGAL REPRESENTATIVES, HEIRS, SUCCESSORS OR ASSIGNS, AND ANY ENTITY IN WHICH DEFENDANTS HAVE OR HAD A MAJORITY OWNERSHIP INTEREST. ALSO EXCLUDED FROM THE SETTLEMENT CLASS ARE THOSE PERSONS WHO FILE VALID AND TIMELY REQUESTS FOR EXCLUSION IN ACCORDANCE WITH THE COURT’S PRELIMINARY APPROVAL ORDER.)

IF YOU ARE A SETTLEMENT CLASS MEMBER, YOU MUST COMPLETE AND SUBMIT THIS FORM IN ORDER TO BE ELIGIBLE FOR ANY SETTLEMENT BENEFITS.

YOU MUST COMPLETE AND SIGN THIS PROOF OF CLAIM AND RELEASE FORM (“PROOF OF CLAIM AND RELEASE FORM”) AND MAIL IT BY FIRST CLASS MAIL, POSTMARKED NO LATER THAN OCTOBER 23, 2019 TO STRATEGIC CLAIMS SERVICES, THE CLAIMS ADMINISTRATOR, AT THE FOLLOWING ADDRESS:

Stemline Therapeutics, Inc. Securities Litigation
c/o Strategic Claims Services
600 N. Jackson St., Ste. 205
P.O. Box 230
Media, PA 19063
Tel.: 866-274-4004
Fax: 610-565-7985
info@strategicclaims.net

YOUR FAILURE TO SUBMIT YOUR CLAIM BY OCTOBER 23, 2019 WILL SUBJECT YOUR CLAIM TO REJECTION AND PRECLUDE YOU FROM RECEIVING ANY MONEY IN CONNECTION WITH THE SETTLEMENT OF THIS ACTION. DO NOT MAIL OR DELIVER YOUR CLAIM TO THE COURT OR TO ANY OF THE PARTIES OR THEIR COUNSEL AS ANY SUCH CLAIM WILL BE DEEMED NOT TO HAVE BEEN SUBMITTED. SUBMIT YOUR CLAIM ONLY TO THE CLAIMS ADMINISTRATOR. IF YOU ARE A SETTLEMENT CLASS MEMBER AND DO NOT SUBMIT A PROPER PROOF OF CLAIM AND RELEASE FORM, YOU WILL NOT SHARE IN THE SETTLEMENT, BUT YOU NEVERTHELESS WILL BE BOUND BY THE ORDER AND FINAL JUDGMENT OF THE COURT, INCLUDING THE RELEASES THEREIN, UNLESS YOU EXCLUDE YOURSELF.

SUBMISSION OF A PROOF OF CLAIM DOES NOT ASSURE THAT YOU WILL SHARE IN THE PROCEEDS OF THE SETTLEMENT.

CLAIMANT’S STATEMENT

1. I (we) purchased or otherwise acquired Stemline Therapeutics, Inc. (“Stemline”) common stock during the Settlement Class Period. (Do not submit this Proof of Claim and Release Form if you did not purchase or otherwise acquire Stemline common stock during the Settlement Class Period.)
2. By submitting this Proof of Claim and Release Form, I (we) state that I (we) believe in good faith that I am (we are) a Settlement Class Member(s) as defined above and in the Notice of Pendency and Proposed Settlement of Class Action (the “Notice”), or am (are) acting for such person(s); that I am (we are) not a Defendant(s) in the Action or anyone excluded from the Settlement Class; that I (we) have read and understand the Notice; that I (we) believe that I am (we are) entitled to receive a share of the Net Settlement Fund, as defined in the Notice; that I (we) elect to participate in the proposed Settlement described in the Notice; and that I (we) have not filed a request for exclusion. (If you are acting in a representative capacity on behalf of a Settlement Class Member [e.g., as an executor, administrator, trustee, or other representative], you must submit evidence of your current authority to act on behalf of that Settlement

Class Member. Such evidence would include, for example, letters testamentary, letters of administration, or a copy of the trust documents.)

3. I (we) consent to the jurisdiction of the Court with respect to all questions concerning the validity of this Proof of Claim and Release Form. I (we) understand and agree that my (our) claim may be subject to investigation and discovery under the Federal Rules of Civil Procedure, provided that such investigation and discovery shall be limited to my (our) status as a Settlement Class Member(s) and the validity and amount of my (our) claim. No discovery shall be allowed on the merits of the Action or Settlement in connection with processing of the Proof of Claim and Release Form.
4. I (we) have set forth where requested below all relevant information with respect to each purchase or acquisition of Stemline common stock, and each sale, if any, of such securities. I (we) agree to furnish additional information to the Claims Administrator to support this claim if requested to do so.
5. I (we) have enclosed photocopies of the stockbroker's confirmation slips, stockbroker's statements, or other documents evidencing each purchase and sale of Stemline common stock listed below in support of my (our) claim. (IF ANY SUCH DOCUMENTS ARE NOT IN YOUR POSSESSION, PLEASE OBTAIN A COPY OR EQUIVALENT DOCUMENTS FROM YOUR BROKER OR TAX ADVISOR BECAUSE THESE DOCUMENTS ARE NECESSARY TO PROVE AND PROCESS YOUR CLAIM.)
6. I (we) understand that the information contained in this Proof of Claim and Release Form is subject to such verification as the Claims Administrator may request or as the Court may direct, and I (we) agree to cooperate in any such verification. (The information requested herein is designed to provide the minimum amount of information necessary to process most simple claims. The Claims Administrator may request additional information as required to efficiently and reliably calculate your Recognized Loss. In some cases, the Claims Administrator may condition acceptance of the claim based upon the production of additional information, including, where applicable, information concerning transactions in any derivatives securities such as options.)
7. I (we) agree and acknowledge that, upon the Effective Date of the Settlement, as detailed in the Notice, and pursuant to the terms of the Stipulation and Agreement of Settlement (the "Stipulation"), I (we) on behalf of myself (ourselves) and my (our) "Related Parties" (as defined in the Stipulation), including without limitation my (our) heirs, joint tenants, tenants in common, beneficiaries, executors, administrators, predecessors, successors, attorneys, insurers and assigns, (or, if I am (we are) submitting this Proof of Claim and Release Form on behalf of a corporation, a partnership, estate or one or more other persons, by it, him, her or them, and by its, his, her or their Related Parties, including without limitation heirs, executors, administrators, predecessors, successors, and assigns) shall have fully, finally, and forever released, resolved, remised, and discharged the Defendants and the Defendants' Related Parties of all "Released Plaintiffs' Claims," including "Unknown Claims," as those terms are defined in the Stipulation.
8. I (we) agree and acknowledge, on behalf of myself (ourselves) and my (our) Related Parties, including, without limitation, my (our) heirs, joint tenants, tenants in common, beneficiaries, executors, administrators, predecessors, successors, attorneys, insurers and assigns (or, if I am (we are) submitting this Proof of Claim and Release Form on behalf of a corporation, a partnership, estate or one or more other persons, by it, him, her or them, and by its, his, her or their Related Parties, including without limitation heirs, executors, administrators, predecessors, successors, and assigns) shall, upon the Effective Date, have been permanently barred and enjoined from prosecuting or attempting to prosecute any Released Plaintiffs' Claims, including Unknown Claims, against any of the Defendants and their Related Parties.
9. "Effective Date" has the meaning set forth in the Stipulation.
10. "Related Parties" has the meaning set forth in the Stipulation.
11. "Released Plaintiffs' Claims" has the meaning set forth in the Stipulation.
12. "Unknown Claims" has the meaning set forth in the Stipulation.
13. I (We) acknowledge that the inclusion of "Unknown Claims" in the definition of claims released pursuant to the Stipulation was separately bargained for and is a material element of the Settlement of which this release is a part.
14. NOTICE REGARDING ELECTRONIC FILES: Certain claimants with large numbers of transactions may request, or may be requested, to submit information regarding their transactions in electronic files. All Claimants MUST submit a manually signed paper Proof of Claim and Release Form listing all their transactions whether or not they also submit electronic copies. If you wish to file your claim electronically, you must contact the Claims Administrator at info@strategicclaims.net or visit their website at www.strategicclaims.net to obtain the required file layout. No electronic files will be considered to have been properly submitted unless the Claims Administrator issues to the Claimant a written acknowledgment of receipt and acceptance of electronically submitted data.

I. CLAIMANT INFORMATION

Name:		
Address:		
City:	State:	ZIP:
Foreign Province:	Foreign Country:	
Day Phone:	Evening Phone:	
Email:		
Social Security Number (for individuals):	OR	Taxpayer Identification Number (for estates, trusts, corporations, etc.):

II. SCHEDULE OF TRANSACTIONS IN STEMLINE THERAPEUTICS, INC. COMMON SHARES

Beginning Holdings:

A. State the total number of shares of Stemline Therapeutics, Inc. (“Stemline”) common shares held at the close of trading on January 19, 2017 (*must be documented*). If none, write “zero” or “0.”

--

Purchases/Acquisitions:

B. Separately list each and every purchase or acquisition of Stemline common shares from January 20, 2017 through May 2, 2017, both dates inclusive, and/or pursuant or traceable to the SPO, and provide the following information (*must be documented*):

Trade Date (List Chronologically) (Month/Day/Year)	Number of Shares Purchased	Price per Share	Total Cost (Excluding Commissions, Taxes, and Fees)

Sales:

C. Separately list each and every sale of Stemline common shares from January 20, 2017 through May 2, 2017, both dates inclusive, and provide the following information (*must be documented*):

Trade Date (List Chronologically) (Month/Day/Year)	Number of Shares Sold	Price per Share	Amount Received (Excluding Commissions, Taxes, and Fees)

Ending Holdings:

D. State the total number of shares of Stemline common shares held at the close of trading on May 2, 2017 (*must be documented*).

If additional space is needed, attach separate, numbered sheets, giving all required information, substantially in the same format, and print your name and Social Security or Taxpayer Identification number at the top of each sheet.

III. SUBSTITUTE FORM W-9

Request for Taxpayer Identification Number:

Enter taxpayer identification number below for the Beneficial Owner(s). For most individuals, this is your Social Security Number. The Internal Revenue Service (“I.R.S.”) requires such taxpayer identification number. If you fail to provide this information, your claim may be rejected.

Social Security Number (for individuals)	or	Taxpayer Identification Number (for estates, trusts, corporations, etc.)
_____		_____

IV. CERTIFICATION

I (We) submit this Proof of Claim and Release Form under the terms of the Settlement Stipulation described in the Notice. I (We) also submit to the jurisdiction of the United States District Court for the Southern District of New York, with respect to my (our) claim as a Settlement Class Member(s) and for purposes of enforcing the release and covenant not to sue set forth herein. I (We) further acknowledge that I am (we are) bound by and subject to the terms of any judgment that may be entered in this Action. I (We) have not submitted any other claim covering the same purchases or sales of Stemline common shares during the Settlement Class Period and know of no other Person having done so on my (our) behalf.

I (We) certify that I am (we are) NOT subject to backup withholding under the provisions of Section 3406 (a)(1)(c) of the Internal Revenue Code because: (a) I am (We are) exempt from backup withholding; or (b) I (We) have not been notified by the I.R.S. that I am (we are) subject to backup withholding as a result of a failure to report all interest or dividends; or (c) the I.R.S. has notified me (us) that I am (we are) no longer subject to backup withholding.

NOTE: If you have been notified by the I.R.S. that you are subject to backup withholding, please strike out the language that you are not subject to backup withholding in the certification above.

UNDER THE PENALTIES OF PERJURY UNDER THE LAWS OF THE UNITED STATES, I (WE) CERTIFY THAT ALL OF THE INFORMATION I (WE) PROVIDED ON THIS PROOF OF CLAIM AND RELEASE FORM IS TRUE, CORRECT AND COMPLETE.

Signature of Claimant (If this claim is being made on behalf of Joint Claimants, then each must sign):

(Signature)

(Signature)

(Capacity of person(s) signing, e.g. beneficial purchaser(s), executor, administrator, trustee, etc.)

Check here if proof of authority to file is enclosed.
(See Item 2 under Claimant's Statement)

Date: _____

THIS PROOF OF CLAIM AND RELEASE FORM MUST BE POSTMARKED NO LATER THAN OCTOBER 23, 2019 AND MUST BE MAILED TO:

Stemline Therapeutics, Inc. Securities Litigation
c/o Strategic Claims Services
600 N. Jackson St., Ste. 205
P.O. Box 230
Media, PA 19063
Fax: (610) 565-7985
info@strategicclaims.net

A Proof of Claim and Release Form received by the Claims Administrator shall be deemed to have been submitted when posted, if mailed by October 23, 2019 and if a postmark is indicated on the envelope and it is mailed first class and addressed in accordance with the above instructions. In all other cases, a Proof of Claim and Release Form shall be deemed to have been submitted when actually received by the Claims Administrator.

You should be aware that it will take a significant amount of time to process fully all of the Proof of Claim and Release Forms and to administer the Settlement. This work will be completed as promptly as time permits, given the need to investigate and tabulate each Proof of Claim and Release Form. Please notify the Claims Administrator of any change of address.

Stemline Therapeutics, Inc. Securities Litigation
c/o Strategic Claims Services
600 N. Jackson St., Ste. 205
Media, PA 19063

IMPORTANT LEGAL NOTICE – PLEASE FORWARD

REMINDER CHECKLIST

- Please be sure to sign this Proof of Claim and Release Form on page 15. If this Proof of Claim and Release Form is submitted on behalf of joint claimants, then each claimant must sign.
- Please remember to attach supporting documents. Do NOT send any stock certificates. Keep copies of everything you submit.
- Do NOT use highlighter on the Proof of Claim and Release Form or any supporting documents.
- If you desire an acknowledgment of receipt of your claim form, please send it Certified Mail, Return Receipt Requested, or its equivalent.
- If you move or change your address, telephone number or email address, please submit the new information to the Claims Administrator, as well as any other information that will assist us in contacting you. NOTE: Failure to submit updated information to the Claims Administrator may result in the Claims Administrator's inability to contact you regarding issues with your claim or deliver payment to you.